[go: up one dir, main page]

WO2008062245A1 - Extraits de la plante eugenia jambolana utilisés dans le traitement du diabète et procédé d'extraction de ceux-ci - Google Patents

Extraits de la plante eugenia jambolana utilisés dans le traitement du diabète et procédé d'extraction de ceux-ci Download PDF

Info

Publication number
WO2008062245A1
WO2008062245A1 PCT/IB2006/002733 IB2006002733W WO2008062245A1 WO 2008062245 A1 WO2008062245 A1 WO 2008062245A1 IB 2006002733 W IB2006002733 W IB 2006002733W WO 2008062245 A1 WO2008062245 A1 WO 2008062245A1
Authority
WO
WIPO (PCT)
Prior art keywords
plant
extract
eugenia
extracts
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/002733
Other languages
English (en)
Inventor
Patell Villoo Morawala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avesthagen Ltd
Original Assignee
Avestha Gengraine Technologies Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avestha Gengraine Technologies Pvt Ltd filed Critical Avestha Gengraine Technologies Pvt Ltd
Priority to PCT/IB2006/002733 priority Critical patent/WO2008062245A1/fr
Publication of WO2008062245A1 publication Critical patent/WO2008062245A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus

Definitions

  • the present invention relates to herbal extracts from Eugenia jambolana species with hypoglycemic activity, which is characterized in delaying of onset and / or management of diabetes by inhibiting the glucose absorption in the intestine and by mimicking and potentiating the insulin activity and also to a method for producing the extract and the use of the extract in the treatment of diabetes.
  • IDDM insulin-dependent diabetes mellitus
  • NDDDM non-insulin-dependent diabetes mellitus
  • IDDM results from insulin deficiency caused by cell-mediated autoimmune destruction of pancreatic beta cells, and generally develops in the young (Bach J F., Insulin-dependent diabetes mellitus as a beta cell targeted disease of immunoregulation. J. Autoimm. 8:439-463,1995).
  • IDDM accounts for approximately 10-15% of the diabetic population worldwide (World Health Organization Study Group. Diabetes mellitus. WHO Tech. Rep. Ser. 727:1-113,1985). In contrast, NIDDM results from a variable combination of insulin resistance and insulin deficiency and generally develops in adults (Jun H S, et al., Pathogenesis of non-insulin- dependent (Type II) diabetes mellitus (NIDDM) Genetic predisposition and metabolic abnormalities. Advanced Drug Delivery Reviews 35:157-177, 1999; DeFronzo R A., The triumvirate beta cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 37:667- 687, 1988).
  • Factors responsible for causing diabetes are heredity and obesity.
  • Heredity increases the susceptibility of beta cells to viral invasions or favor the development of autoimmune antibodies against the beta cells, thus leading to their destruction.
  • Obesity decreases the number of insulin receptors in the insulin target cells throughout the body. Hence, the amount of insulin present is inadequate to induce its usual metabolic effects.
  • blood glucose levels goes as high as 1200 mg/dl are known to occur which is 12 times higher than the normal. Levels of 300 mg/dl to 500 mg/dl are common in diabetic patients.
  • Diabetic Symptoms which may arise due to pathological physiology of Insulin lack, are Polyuria, Polydipsia, Polyphagia, Asthenia and diminished utilization of carbohydrates for energy.
  • Diabetic Neuropathy Diabetic Diarrhea
  • Urinary retention Gustatory Swelling
  • Papillary Reflexes Cardiac Autonomic Disturbances
  • Collagen Disturbances Collagen Disturbances.
  • Diabetic Neuropathy is the most common and affects patients at earlier stages.
  • the usual methods for diagnosing diabetes are based on various chemical tests of urine and the blood viz, Urinary Sugar, Fasting Blood Glucose Level, Postprandial Blood Glucose Level (Glucose Tolerance Test) and Acetone breath.
  • Jamun seeds are widely used in Indian folk medicine for the treatment of diabetes mellitus (Prince P. S., Menon V. P. and Pari L. J Ethnopharmacol; 1998 May; 61 (1): 1-7). It has been reported that the aqueous extract of Jamun seeds has hypoglycemic action.
  • Eugenia jambolana or Sy ⁇ ygium cumini L belongs to the myrtaceae plant family. Common names are Java plum, black plum, jambul and Indian blackberry. It grows naturally is clayey loam soil in tropical as well as sub-tropical zones. It is widely cultivated in Haryana as well as the rest of the Indo-Gangetic plains on a large scale. Its habitat starts from Sri and extends up to Afghanistan. It is generally cultivated as a roadside avenue tree as well.
  • Figure 4 Shows Insulin mimetic activity of the 3.33 ⁇ g of Eugenia 70% ethanol extract compared to that of 1OnM Insulin using tritiated glucose as an energy source in 3T3 L-I adipocyte cell lines.
  • Figure 5 Shows Insulin sensitization activity of the 3.33 ⁇ g Eugenia 70% ethanol extract compared to that of 1OnM Insulin using tritiated glucose as an energy source in 3T3 L-I adipocyte cell lines.
  • Figure 6 Shows Insulin mimetic activity of the 3.33 ⁇ g of Eugenia 70% ethanol extract compared to that of 1OnM Insulin using tritiated glucose as an energy source in C2C12 myocyte cell lines.
  • Another object of the invention is to provide a method of treating diabetes comprising administering to a person in need thereof an anti- diabetic or hypoglycemic effective amount of a composition comprising the extracts of the plant Eugenia jambolana.
  • Plant material suitable for preparation of the plant extract for inclusion of the therapeutic composition of the invention is derived from a potential plant administered to a person suffering from diabetes, which results in the lowering of the blood glucose level of the patient. Administration of the composition to the patient both prevented and treated incidences of clinical diabetes.
  • the plant material employed in the extraction process can be the entire potential plant, or it can be one or more distinct tissues from the plant for example, leaves, seeds, roots, stems, flowers, or various combinations thereof but preferably the seed of the plant.
  • the plant material can be treated prior to extraction, for example, by drying, freezing, lyophilizing, or some combination thereof.
  • the plant material can be fragmented and/or homogenized by some means such that a greater surface area is presented to the solvent.
  • the plant material can be crushed or sliced mechanically, using a grinder or other device to fragment the plant parts into small pieces or particles, or the plant material can be frozen liquid nitrogen and then crashed or fragmented into smaller pieces.
  • the coarse powder of herbal material is soaked in 70% ethanol water for a fixed duration at room temperature with constant stirring in pharmaceutical grade solvent extractor.
  • the extract is passed though a continuous centrifuge rotating at 3000rpm to separate extract supernatant and material debris.
  • the clear supernatant obtained is concentrated to 1/10 volume using concentrator and is treated with food grade organic solvents in a definite proportion to remove any unpleasant smell, taste and color.
  • the concentrated and organoleptically optimized extract is dried completely using either spray drier or vacuum drier to get powdered extract.
  • Thus prepared dried extract is stored in airtight food grade plastic bins and the same is taken through several in-vitro cells free and cell based bioassay to validate the extract efficacy.
  • the extract is generally produced by contacting the solid plant material with a solvent with adequate mixing and for a period of time sufficient to ensure adequate exposure of the solid plant ' material to the solvent such that inhibitory activity present in the plant material can be taken up by the solvent.
  • the solvent extraction process may be selected from direct and successive extraction types such as extraction from plant parts in soxhlet apparatus or in flasks at room temperature or at higher temperature with polar and/or non-polar solvent (s). Regardless of the number of extraction -processes, each extraction process typically is conducted over a period of time between about 6 hours to 24 hours at room temperature. Adequate contact of the solvent with the plant material can be encouraged by shaking the suspension. The liquid fraction is then separated from the solid (insoluble) matter resulting in the generation of two fractions: a liquid fraction, which is the potential extract, and a solid fraction. Separation of the liquid and solid fractions can be achieved by one or more standard processes known to those skilled in art.
  • the present invention contemplates the large-scale preparation of the selected plant extracts of the invention.
  • Such extracts can be prepared on a commercial scale by repeating the extraction process that lead to the isolation of the extract of interest.
  • the small-scale extraction procedure can simply be scaled up and additional steps of quality control can be included to ensure reproducible results for the resulting extracts.
  • the potential extracts obtained thereof are concentrated and solubilised in an appropriate solvent preferably ethyl acetate.
  • an appropriate solvent preferably ethyl acetate.
  • organic solvents include but are not limited to, di-ethyl ether, hexane, heptane, dichloromethane, ethyl acetate, butyl alcohol, ether, acetone and the combinations thereof.
  • Free radicals are constantly being generated in the body, as a result of the normal metabolic processes. Under physiological conditions, damage due to free radicals is countered by antioxidants. Sometimes, excessive free radical formation occurs in the body, and the antioxidant systems in the body cannot cope with the situations, i.e., the pro-oxidants overwhelm the antioxidants. This situation is known as oxidative stress. Thus, oxidative stress is a general term used to describe a state of potential oxidative damage caused by free radicals.
  • NO nitric oxide
  • the weight of experimental and human evidence supports a clear role for increased oxidant stress in many of the proposed biochemical pathways linked to the microvascular and microvascular complications of diabetes. In particular, very recent evidence has underscored the particular role the elevated glucose plays in oxidative modification of LDL by a superoxide dependent pathway, and has demonstrated that, in people with poorly controlled IDDM 5 there is increased LDL oxidation associated with reduced antioxidant defenses.
  • Free radical reactions and non-enzymatic glycosylation may play important roles not only in the development of diabetes, but also in its complications, Hayakawa et al, Free radicals and diabetes mellitus, Nippon Ronen Igakkai Zasshi. 1990 Mar; 27(2): 149-54.
  • the isolated extracts were used to estimate its free radical scavenging potency relative to ascorbic acid by using Calorimetric-DPPH method (Polterait O. (1997) Anti Oxidants and free-radical Scavengers of Natural origin Current Org. Chem. 1. 415-440).
  • the Eugenia 70% ethanol extract isolated from the seeds of the plant showed nearly 60% of free radical scavenging potency equivalent to that of ascorbic acid.
  • apple'polyphenols have a positive effect on diabetes and insulin resistance in animals and humans
  • European researchers announced that an apple-derived polyphenol, phlorizin, "completely normalized insulin response" in diabetic rats.
  • scientists at the National Institutes of Health in the U.S. gave this same apple polyphenol to mice.
  • Two weeks of treatment "significantly decreased blood glucose levels” in diabetic mice.
  • Whole body fat mass was also “significantly reduced.”
  • the total polyphenol content of the Eugenia 70% ethanol extract was estimated relative to gallic acid using Calorimetric - Singleton method (Singleton, V.L. and Ropssi, J. A. Jr (1965). Calorimetry of total phenolics with phosphomolybdic - phosphotungstic acid reagent, Am. J. Enol. Vitig. 16: 144 - 158).
  • the Eugenia 70% ethanols extract showed 53.4 ⁇ 2.25 % total phenol content equivalent to gallic acid clearly indicative of the potential beneficial effects the extracts possess with respect to the management of diabetes and its medicative properties.
  • oligosacharrides (carbohydrates having 2 to 10 glucose residues connected by 1-4 or 1-6 ⁇ -D-glycosidic linkage) into monosaccharides by alpha- glucohydrolase-catalyzed enzymatic reactions was tested for Eugenia 70% ethanol extract using Calorimetric - para-nitro-phenyl (pNP) release method using pNP-a-D- glucoside (Halvorson. H, 'Methods in enzymology' VoI 8, Academics Press, New York, 1966, p 559-562).
  • the Eugenia 70% ethanol extract showed greater ⁇ -glucosidase inhibition potential (IC50 value of 32.79 ⁇ g/ml) relative to the commercially available ⁇ - glucosidase inhibitor, acarbose (IC50 value of 146.55 ⁇ g/ml) for 0.2 ⁇ -glucosidase enzyme units at standard enzymatic reaction conditions.
  • Insulin-stimulated glucose uptake in adipose tissue and striated muscle is critical for reducing postprandial blood glucose concentration and the dysregulation of this process is one of the hallmarks of Type -II Diabetes mellitus (Non Insulin dependent). Oral therapies for Diabetes mellitus have emerged out of this interest and are widely used still today. But rather than acting by rnirnicking insulin, these drugs acts either by stimulating insulin release [Sulphonymrease], potentiating insulin action (thiazolidinedione). or lowering hepatic glucose production (biguanides). Various amounts of Eugenia 70% ethanol extract (0.034 ⁇ g to 33.4 ⁇ g) are tested for insulin mimetic and sensitization effects with / without insulin.
  • Radio labeled glucose is used to measure the changes in the level of glucose uptake activity of the adipocyte cells in response to treatment with samples in the presence or absence of insulin.
  • the assay is performed in a 96-well microtiter plate format and the counts per minute are measured using a radioactive counter. The count per minute can be measured on a microtitre plate by radioactive counter.
  • the present invention envisages the method of treating diabetes and other related diseases thereof by administering an effective amount of the therapeutic composition comprising the single plant extract or the screened plant extracts purified there from in combination.
  • the therapeutic compositions of the invention can be administered alone or in combination with one or more standard anti-diabetic therapeutics.
  • the present invention also contemplates the administration of sub-optimal doses of the therapeutic composition, for example, chemotherapeutic drug(s), in combination with the therapeutic composition.
  • one or more plant extracts in order to prepare a therapeutic combination, one or more plant extracts is first selected and then the efficacy of the extract(s) in controlling diabetes and maintaining glucose homeostasis is determined using standard techniques as one of those outlined above.
  • the efficacy of the one or more plant extract alone is then compared to the efficacy of the one or more plant extract in combination with varying amounts of another component i.e., another plant extract.
  • the invention also contemplates the combination the plant extract with another synthetic inhibitor.
  • a combination that demonstrates therapeutic index in comparison to the individual properties is considered to be an effective combination.
  • compositions comprising two or more plant extracts various ratios of the constituent plant extracts are contemplated.
  • the ratio of extract A to extract B can vary anywhere between 1:99 and 99:1.
  • anywhere between 99:1 and 1:99 it is meant that the ratio of the two extracts can be defined by any ratio within this ratio can be between 98:2 and about 1:99 between about 98:2 and 2:98, between 97:3 and 1:99, between 97:3 and 2:98, between 97:3 and 3:97, etc.
  • the present invention contemplates the ratio of the two extracts is between about 90:10 and 10:90, 80:20 and 20:80, 70:30 and 30:70, 60:40 and 40:60 or 50: 50.Analogous ratios are contemplated for compositions comprising more than two or more plant extracts.
  • the formulations of the present invention contain at least an effective amount of the therapeutic composition.
  • the effective amount is considered to be that amount of the composition, in weight percent of the overall formulation, which must be present in order to produce the desired therapeutic effect.
  • the effective amount may vary, depending upon, for example the disease to be treated and the form of administration.
  • the therapeutic composition will be present in an amount ranging from about 1% to 100% by weight of the formulation, 10% to about 90% by. weight of the formulation, 20% to about 80% by weight of the formulation, 30% to 70% by weight of the formulation, from about 40% to 60% by weight of the formulation and about 50% by weight of the formulation.
  • the present invention contemplates the use of the therapeutic compositions at various stages in the disease development and progression, including in the treatment of early stage, or advanced and/or aggressive stage of hyperglycemia, diabetes or related disorders.
  • the administration of the therapeutic composition comprising the isolated and screened extracts to mammal having an early stage of the disorder can help to attenuate the progression of the disease.
  • the dosage of the therapeutic composition to be administered is not subject to defined limits, but will usually be an effective amount. However it will be understood that the actual amount of the composition to be administered will be determined by a physician, in the light of the relevant circumstances, including the exact condition to be treated, the chosen route of administration, the actual composition administered, the age, the weight, and the response of the individual patient and the severity of the patient's symptoms.
  • the dosage ranges are not intended to limit the scope of the invention in any way.
  • the therapeutic composition can be formulated as a pharmaceutical or naturopathic formulation such as phytoceuticals or nutraceuticals, for oral, topical, rectal or parenteral administration or for administration by inhalation or spray.
  • the phytoceutical or naturopathic formulation may comprise the one or more plant extracts in dosage unit formulations containing the conventional non-toxic physiologically acceptable carriers, adjuvants and vehicles.
  • the pharmaceutical or naturopathic formulations may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion hard or soft capsules, or syrups or elixirs.
  • the therapeutic compositions of the invention may be formulated as phytoceuticals, or nutraceuticals.
  • Phytoceuticals may optionally comprise other plant-derived -components and can therefore be delivered by such non-limiting vehicles as teas, tonics, juices or syrups.
  • Nutraceuticals ' contemplated by the present invention may provide nutritional and/or supplemental benefits and therefore be delivered, for example as foods, dietary supplements, extracts, beverages or the like.
  • Phytoceutical- and nutraceuticals can be administered in accordance with conventional treatment programs and/or may be a part of the dietary or supplemental program.
  • Formulations intended for oral use may be prepared according to methods known in art for the manufacture of pharmaceutical compositions and may contain one or more agents selected from the group of flavoring agents, coloring agents and preserving agents in order to provide palatable preparations.
  • Tablets contain the active ingredient in admixture with suitable non-toxic physiologically acceptable excipients including, for example, inert diluents, such as calcium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, such as com starch, or alginic acid, binding agents, such as starch, gelatine or acacia, and lubricating agents, such as magnesium stearate, stearic acid or talc.
  • suitable non-toxic physiologically acceptable excipients including, for example, inert diluents, such as calcium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, such as com starch, or alginic acid, binding agents, such as starch, gelatine or acacia, and lubricating agents, such as magnesium stearate, stearic acid or talc.
  • the tablets can be uncoated, or they may be coated by
  • additives or carriers can be incorporated into the orally ,delivered pharmaceutical naturopathic formulations or the invention.
  • Optional additives of the present composition include, without limitation, phospholipids, such as phosphatidyl glycerol, phosphotidyl inositol, phosphotidyl serine, phosphotidyl choline, phosphotidyl ethanolamine as well as
  • compositions for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatine capsules wherein the active ingredient is mixed with water or an oil based medium such as peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water or an oil based medium such as peanut oil, liquid paraffin or olive oil.
  • Oily suspensions may be formulated by suspending the plant extract(s) in a vegetable oil, for example, arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Flavoring agents may be added to provide palatable oral preparations. These formulations can be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation suitable for an aqueous suspension by the addition of water provide the active ingredient in admixture with dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents, sweetening, flavoring and coloring agents may also be present.
  • a comestible that is to say, a foodstuff comprising at least an extract of the invention, typically in dried form, such as in a lyophilised form.
  • cosmetibles may contain more than one extract of the invention and may be used.
  • Such foodstuffs may be used in a prophylactic manner and may contain further extracts having a similar function to the first added extract or further added extracts may be added that have a different prophylactic function.
  • a foodstuff could either comprise extracts that provide for a comestible having a single functional aspect, or a comestible may have a multi-functional prophylactic effect against, two or more disease types.
  • the type of foodstuff or comestible to which at least an extract of the invention may be added includes any processed food such as confectioneries, baked products including breads such as loafs, and flat breads such as pitta bread, naan bread and the like, cakes, snack foods such as museli bars, compressed dried fruit bars, biscuits, daily products such as yoghurts, milk and milk-based products such as custards, cream, cheese, butter and creme fraiche, simulated dairy food product such as Elmlea products, fruits and vegetable juices, aerated drinks, such as carbonated soft drinks and non-aerated drinks such as squashes, soya milk, rice milk and coconut milk and the like, pastas, noodles, vegetables, seed and nut oils, fruited oils such as sunflower oil, rapeseed oil, olive oil, walnut, hazelnut, and sesame seed oil and the like, and frozen confectionaries such as ice cream, iced yoghurts and the like.
  • processed food such as confectionerie
  • the present invention relates to mixtures, which can be isolated from Eugenia jambolana, L seeds (Myrtaceae family) for the management of an important clinical problem like diabetes.
  • the preparation method is exemplified as follows:
  • Eugenia jambolana seeds are selected and tested for seed quality by pharmacognosy techniques.
  • the authentic plant material is procured for bioactive extraction.
  • Good quality Eugenia jambolana seeds are macerated into solvent extractable seed powder of preferable size of lOO ⁇ m.
  • the bioactive extract is prepared from the seeds.70% ethanol water mixtures are used as solvent for the preparation of the bioactive extract.
  • the extraction process is carried out in a solvent extraction vessel of 100-liter capacity. The extraction process is undertaken at a temperature of 25 0 C and for a duration of 240 minutes. The extraction is carried out with constant stirring at the rate of 200 rpm allowing the heavier particles in -the extraction mixture to settle down and later the mixture is allowed to stand undisturbed for 120 minutes.
  • the liquid phase of the extract is clarified by centrifugation.
  • the centrifugation process is undertaken at 3000 rpm and at room temperature.
  • the clarified extract was then concentrated to 1/10 of the total volume.
  • the concentrated extract (two parts) is mixed well with a moderately non- polar solvent such as ethyl acetate (one part) in an extraction vessel for 60 minutes and left undisturbed for 120 minutes.
  • the lower water phase is then separated and dried completely to powder using either spray drier or vaccum dried under reduced pressure.
  • the powdered extract is then stored in an airtight plastic container. This extract is further used for all the biochemical, physiochemical, heavy metal, natural toxin and detailed, efficacy study.
  • the total polyphenol content of the Eugenia 70% ethanol extract is estimated relative to gallic acid using Calorimetric - Singleton method (Singleton, V.L. and Ropssi, J.A. Jr (1965). Calorimetry of total phenolics with phosphomolybdic - phosphotungstic acid reagent, Am. J. Enol. Vitig. 16: 144 - 158).
  • the Eugenia 70% ethanols extract showed 53.4 + 2.25 % total phenol content equivalent to gallic acid, which is shown in figure 2.
  • oligosacharrides carbohydrates having 2 to 10 glucose residues connected by 1-4 or 1-6 alpha-D-glycosidic linkage
  • pNP Calorimetric - para-nitro-phenyl
  • the Eugenia 70% ethanol extract showed greater ⁇ -glucosidase inhibition potential (IC50 value of 32.79 ⁇ g/ml) relative to the commercially available - ⁇ glucosidase inhibitor, acarbose (IC50 value of 146.55 ⁇ g/ml) for 0.2 ⁇ -glucosidase enzyme units at standard enzymatic reaction conditions.
  • Example 5 Ih- vitro screening of Eugenia 70% ethanol extract for glucose uptake
  • Insulin-stimulated glucose uptake in adipose tissue and striated muscle is critical for reducing postprandial blood glucose concentration and the dysregulation of this process is one of the hallmarks of Type -II Diabetes mellitus (Non Insulin dependent). Oral therapies for Diabetes mellitus have emerged out of this interest and are widely used still today. But rather than acting by mimicking insulin, these drags acts either by stimulating insulin release [Sulphonylurease], potentiating insulin action (thiazolidinedione) or lowering hepatic glucose production (biguanides).
  • Various amounts of Eugenia 70% ethanol extract (0.034 ⁇ g to 33.4 ⁇ g) are tested for insulin mimetic and sensitization effects with / without insulin.
  • Radio labeled glucose is used to measure the changes in the level of glucose uptake activity of the adipocyte cells in response to treatment with samples in the presence or absence of insulin.
  • the assay is performed in a 96-well microtiter plate format and the counts per minute are measured using a radioactive counter. The count per minute can be measured on a microtitre plate by radioactive counter.
  • the amount that showed best insulin mimetic and sensitization activity in 3T3L-1 adipocyte cells and C2C12 myocyte cells for glucose uptake was around 0.334 ⁇ g.
  • the method followed for screening is as follows:
  • Preadipocytes (3T3L-1) and premyocytes (C2C12) are cultured in DMEM containing 10%FCS, 4mM Glutamine, 2 % NaHCO3 and antimycotic, in an atmosphere of 5% CO2 at 370C, separately.
  • Myoblasts are cultured up to 80% confluency and the cells are sub- cultured at three-day intervals.
  • 20,000 of preadipocytes and myocytes are seeded separately in each well of a 96 well plate and differentiated for 48 hours in DMEM:F12(1:1), 0.5mMIBMX, 0.25mM Dexmethasone and lug Insulin for 48hrs followed by incubation with lug of Insulin for 8hours.
  • the ability of the plant extract to induce glucose uptake is tested in two different ways 1) glucose uptake in presence of insulin (extract 4- insulin) and 2) glucose uptake in absence of insulin (extract alone). Therefore incubate in duplicate (one set to evaluate glucose uptake in presence of insulin i.e. extract + insulin and other set without insulin i.e. extract alone) with different concentration of extracts (300 ⁇ g/well, 30 ⁇ g/well, 3 ⁇ g/well and 0.3 ⁇ g/well) in triplicates for 18 hours at 370 C and 5%CO2 lOO ⁇ l of DMEM. The medium is then removed and the cells are incubated with KRH buffer (100 microliters) at 37 0 C and 5% CO2 for 10 minutes. Cells are incubated with insulin.
  • KRH buffer 100 microliters
  • the cells are washed three times with ice-cold KRH buffer (lOO ⁇ l). KRH buffer is removed and 20 ⁇ l 1% Triton X is added to each well to lyse the cells and incubate for 10 min at 37°C and 5%CO 2 . 200 ⁇ l of Aqualite is added per well and the supernatant is transferred back to the plates and counted on a micro-titer plate radioactive counter.
  • the results obtained for insulin mimetic and sensitization potential of Eugenia 70% ethanol extract is depicted in figure 4 to figure 7 using differentiated adipocyte and myocytes. All the observed values of glucose uptake activity are blank corrected using the control (cells alone background value). These values are normalized with MTT cell viability assay values for the corresponding extracts. The degree of insulin mimetic/sensitization activity of each sample concentration is calculated as a percentage of that observed using 1OnM insulin alone.
  • Example 6 In- vivo efficacy screening using Sprague dawley rats In-vivo efficacy screening of Eugenia 70% ethanol extract was done using Sprague dawley rats and the procedure undertaken is as follows:
  • Sprague dawley rats weighing ⁇ 250g with a variation of ⁇ 20% of the mean weight are selected for In-vivo efficacy screening of Eugenia 70% ethanol extract.
  • the number of animals per dose group is five and is kept for examination and acclimatization for a week period at the start of the study.
  • the total number of dose groups is six along with vehicle control.
  • the different groups are Gl -Vehicle control, G2-Diabetic control, G-3 Diabetic animals treated with Pioglitazone (Standard anti-diabetic drug).
  • G-4 Eugenia 70% ethanol extract 50 mg/kg-body weight
  • G-5 Eugenia 70% ethanol extract 125 mg/kg-body weight
  • G-6 Eugenia 70% ethanol extract 200 mg/kg-body weight.
  • Blood is collection under CO 2 anesthesia by retro orbital (ROP) plexus method and FBG analysis.
  • Rats are fed with 5 % glucose water for two days before STZ injection and are fasted for 12 hours before adrninistering streptozotocin.
  • the rats are injected intra-peritoneal with 45mg/kg- body weight of streptozotocin in a citrate buffer ph: 4.5 and allowed for week recovery.
  • Rats are fasted for 12 hours after 7 th day of STZ injection and blood collected in heparin as the anti-coagulant, under CO 2 anesthesia and analyzed for FBG. Rats that have the range of FBG beyond 250 mg/dl and above are considered for the study.
  • the in-vivo efficacy screening of Eugenia 70% ethanol extract at different concentrations is started and the dosing is 50, 125 and 200mg per kg body with 0.5 percent of carboxyl-methyl-cellulose (CMC) as vehicle.
  • CMC carboxyl-methyl-cellulose
  • the fasting blood glucose lowering potential of the Eugenia 70% ethanol extracts at different concentrations are illustrated in figure 9.
  • the diabetic control rat group showed 246% increase in their fasting blood glucose levels compared to the baseline values of the same group at the start of the study.
  • the group treated with pioglitazone showed 31.37% increase, while Eugenia 70% ethanol extract at 50, 125 and 200mpk showed 50% increase, 17.6% decrease and 39.36% increase respectively from their baseline values at the end of 35 days.
  • the glucose lowering response of 125 and 200 mpk Eugenia 70% ethanol extracts are on par with the response of pioglitazone at 20mpk. The results have been represented in Table No. 2
  • Diabetic control rats showed 84.35% of HbAIc compared to the control rats (38.19%), pioglitazone treated rats (73.63%) 50m ⁇ k (50.04%) and 125mpk Eugenia 70% ethanol extract treated rats (86.30%).

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne des extraits d'herbes aromatiques provenant de l'espèce Eugenia jambolana ayant une activité hypoglycémique, qui est caractérisée en ce qu'elle retarde l'apparition et/ou la gestion d'un diabète par inhibition de l'absorption du glucose dans l'intestin et par simulation et potentialisation de l'activité de l'insuline. L'invention concerne également un procédé pour produire lesdits extraits et l'utilisation de ces extraits dans le traitement du diabète.
PCT/IB2006/002733 2006-09-08 2006-09-08 Extraits de la plante eugenia jambolana utilisés dans le traitement du diabète et procédé d'extraction de ceux-ci Ceased WO2008062245A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2006/002733 WO2008062245A1 (fr) 2006-09-08 2006-09-08 Extraits de la plante eugenia jambolana utilisés dans le traitement du diabète et procédé d'extraction de ceux-ci

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2006/002733 WO2008062245A1 (fr) 2006-09-08 2006-09-08 Extraits de la plante eugenia jambolana utilisés dans le traitement du diabète et procédé d'extraction de ceux-ci

Publications (1)

Publication Number Publication Date
WO2008062245A1 true WO2008062245A1 (fr) 2008-05-29

Family

ID=38007334

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/002733 Ceased WO2008062245A1 (fr) 2006-09-08 2006-09-08 Extraits de la plante eugenia jambolana utilisés dans le traitement du diabète et procédé d'extraction de ceux-ci

Country Status (1)

Country Link
WO (1) WO2008062245A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6114M (fr) * 1967-01-19 1968-06-17
FR2465484A1 (fr) * 1979-09-21 1981-03-27 Urwerg Suzanne Extrait vegetal a proprietes antidiabetiques et son procede de preparation
WO2000074698A1 (fr) * 1999-06-04 2000-12-14 Indian Council Of Medical Research Produit therapeutique a base de plantes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6114M (fr) * 1967-01-19 1968-06-17
FR2465484A1 (fr) * 1979-09-21 1981-03-27 Urwerg Suzanne Extrait vegetal a proprietes antidiabetiques et son procede de preparation
WO2000074698A1 (fr) * 1999-06-04 2000-12-14 Indian Council Of Medical Research Produit therapeutique a base de plantes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARAI I ET AL: "Improving effects of the extracts from Eugenia uniflora on hyperglycemia and hypertriglyceridemia in mice.", JOURNAL OF ETHNOPHARMACOLOGY 15 DEC 1999, vol. 68, no. 1-3, 15 December 1999 (1999-12-15), pages 307 - 314, XP002434035, ISSN: 0378-8741 *
KOHLI K R ET AL: "EUGENIA-JAMBOLANA A PLANT DRUG WITH POTENTIAL ANTIDIABETIC PROPERTY A REVIEW", JOURNAL OF SCIENTIFIC RESEARCH IN PLANTS AND MEDICINES, YOGI PHARMACY, HARDWAR,, IN, vol. 6, no. 1-4, 1985, pages 21 - 28, XP000940820, ISSN: 0253-7249 *
SAGRAWAT, H. ET AL: "Pharmacological potential of Eugenia jambolana: a review", PHARMACOGNOSY MAGAZINE , 2(6), 96-105 CODEN: PMHACG; ISSN: 0973-1296, 1 June 2006 (2006-06-01), XP009083973 *
TEIXEIRA, C. C. ET AL: "Absence of antihyperglycemic effect of jambolan in experimental and clinical models", JOURNAL OF ETHNOPHARMACOLOGY , 71(1,2), 343-347 CODEN: JOETD7; ISSN: 0378-8741, 2000, XP002434036 *

Similar Documents

Publication Publication Date Title
Rahmatullah et al. Antihyperglycemic and antinociceptive activity evaluation of methanolic extract of whole plant of Amaranthus Tricolor L.(Amaranthaceae).
Ogbonnia et al. Evaluation of acute and subacute toxicity of Alstonia congensis Engler (Apocynaceae) bark and Xylopia aethiopica (Dunal) A. Rich (Annonaceae) fruits mixtures used in the treatment of diabetes
El Batran et al. Some toxicological studies of Momordica charantia L. on albino rats in normal and alloxan diabetic rats
KR101412221B1 (ko) 구기자잎 추출 분말과 베타인을 유효성분으로 함유하는 항비만 조성물
Zhang et al. Safety evaluation of a triterpenoid-rich extract from bamboo shavings
US20160243176A1 (en) Extracts from plants of the moringaceae family and methods of making
JP6419573B2 (ja) カシューアップル抽出物を含む組成物
JP2020514416A (ja) ハーブ組成物
US20110064833A1 (en) Synergistic herbal composition and process of preparation thereof
KR101385191B1 (ko) 치커리 추출물의 근육 손상 예방, 치료 또는 개선을 위한 용도
KR101400368B1 (ko) 돌콩의 열처리 분말 또는 추출물을 유효성분으로 하는 당뇨병 및 당뇨합병증의 예방 및 치료를 위한 조성물
EP1369123A1 (fr) Produit medical contenant des rhizomes de lotus et procédé de préparation
Nainwal et al. Study of antihyperlipidemic effect on the juice of the fresh fruits of Lagenaria siceraria
WO2008142702A1 (fr) Composition bioactive alimentaire ayurvédique / fonctionnelle synergique [cincata]
KR20150117514A (ko) 달맞이꽃 추출물을 유효성분으로 함유하는 미소중력하 또는 신경손상으로 인한 근위축 예방 또는 치료용 약학 조성물
Anaga et al. Antihyperglycaemic Properties of the Ethyl acetate Extract of Dennettia tripetala in Diabetic Rats.
WO2008059310A1 (fr) Extraits aqueux de cinnamomum zeylanicum et leurs applications pour traiter des troubles associés au diabète
WO2008136013A1 (fr) Extrait organoleptiquement amélioré de salacia et méthode associée (minora)
WO2008062245A1 (fr) Extraits de la plante eugenia jambolana utilisés dans le traitement du diabète et procédé d'extraction de ceux-ci
WO2008041049A1 (fr) Extraits végétaux de cinnamomum zeylanicum destinés au traitement du diabète et procédé d'extraction de celui-ci
WO2008029191A1 (fr) Extraits aqueux d'eugenia et leur application pour traiter des troubles associés au diabète
KR20090039837A (ko) 아카시아속 나무 껍질 유래물을 함유하는 항비만 조성물
US20100129478A1 (en) Plant Extracts and Methods and Uses Therefore
KR101508561B1 (ko) 귀리를 포함하는 혼합 생약재 추출물을 함유하는 당뇨병의 예방 또는 치료용 약학조성물
KR20130059741A (ko) 민대극 추출물을 포함하는 관절염 예방 및 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06808921

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06808921

Country of ref document: EP

Kind code of ref document: A1